Results 71 to 80 of about 14,309 (181)

Efectividad del interferón peguilado alfa 2a más ribavirina para la hepatitis crónica C en la práctica

Acta Gastroenterológica Latinoamericana, 2010
Antecedentes. En la actualidad el tratamiento estándar y consensuado de la infección crónica por el virus de la hepatitis C se basa en la combinación de dos fármacos: interferón peguilado y ribavirina.
Nelia Hernández, Germán Mescia, Carmen Pollio, Gabriela Robaina, Laura Quintana, Carla Bianchi   +5 more
doaj  

Pharmacists' role in multidisciplinary diagnosis and treatment in adverse reactions: A case report of interferon alfa-2b induced severe lupus. [PDF]

Medicine (Baltimore), 2022
Chen H, Qiu X, Wang J, Wei H.
europepmc   +1 more source

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients. [PDF]

Infect Drug Resist, 2023
He J, Guo Y, Zhang Y, Han J, Chen J, Jia Y, Ma Z, Wu J, Zhang S, Li F, Mao R, Zhang J.   +11 more
europepmc   +1 more source

Congenital Zika Syndrome Is Associated With Interferon Alfa Receptor 1. [PDF]

Front Immunol, 2021
Azamor T, Cunha DP, da Silva AMV, Bezerra OCL, Ribeiro-Alves M, Calvo TL, Kehdy FSG, Manta FSN, Pinto TGT, Ferreira LP, Portari EA, Guida LDC, Gomes L, Moreira MEL, de Carvalho EF, Cardoso CC, Muller M, Ano Bom APD, Neves PCDC, Vasconcelos Z, Moraes MO.   +20 more
europepmc   +1 more source

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys). [PDF]

Leuk Res Rep, 2023
Okikiolu J, Woodley C, Cadman-Davies L, O'Sullivan J, Radia D, Garcia NC, Harrington P, Kordasti S, Asirvatham S, Sriskandarajah P, Saunders J, Saha C, Sanchez I, deLavallade H, McLornan DP, Harrison CN.   +15 more
europepmc   +1 more source

Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)

Современная ревматология
Objective: to evaluate the efficacy and safety of the type I interferon (IFN) receptor inhibitor anifrolumab (AFM, Safnelo®) in patients with systemic lupus erythematosus (SLE) in real-life clinical practice over an observation period of 6 months ...
T. M. Reshetnyak, E. A. Aseeva, A. A. Shumilova, N.  Yu. Nikishina, S. I. Glukhova, S. Yu. Shkireeva, A. M. Lila   +6 more
doaj   +1 more source

Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma. [PDF]

Front Oncol, 2021
Jia DD, Niu Y, Zhu H, Wang S, Ma T, Li T.   +5 more
europepmc   +1 more source

Conjunctival Tarsal Actinic Keratosis Treated with Interferon Alfa-2b: A Rare Case Report and Literature Review. [PDF]

Case Rep Ophthalmol Med, 2021
Gimeno-Carrero M, Suárez-Fernández MJ, Alonso-Martín B, de-Pablo-Cabrera A, Garrido-Ruíz MC, Mencía-Gutiérrez E.   +5 more
europepmc   +1 more source

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma. [PDF]

Cancer Discov, 2022
Grossmann KF, Othus M, Patel SP, Tarhini AA, Sondak VK, Knopp MV, Petrella TM, Truong TG, Khushalani NI, Cohen JV, Buchbinder EI, Kendra K, Funchain P, Lewis KD, Conry RM, Chmielowski B, Kudchadkar RR, Johnson DB, Li H, Moon J, Eroglu Z, Gastman B, Kovacsovics-Bankowski M, Gunturu KS, Ebbinghaus SW, Ahsan S, Ibrahim N, Sharon E, Korde LA, Kirkwood JM, Ribas A.   +30 more
europepmc   +1 more source

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study. [PDF]

Int J Infect Dis, 2021
Pandit A, Bhalani N, Bhushan BLS, Koradia P, Gargiya S, Bhomia V, Kansagra K.   +6 more
europepmc   +1 more source